Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

Viking Therapeutics's obesity/diabetes candidates and strong financials position it for success. Read here for an investment ...

Rhythm Pharmaceuticals is advancing its oral obesity drug bivamelagon to Phase III studies after it significantly reduced ...

Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

DexCom has significant room to grow in its core market, despite disappointing results last year. One of Warren Buffett's ...

Novo Nordisk has been boosted by data for an oral obesity therapy, amycretin, that was more effective than injectable Wegovy at reducing weight in a clinical trial.

Eli Lilly and Company’s LLY stock has declined 15.7% in the past year. The first-quarter earnings miss, guidance cut and some ...

Shares in Novo Nordisk have risen sharply on new weight-loss data with an injectable formulation of new obesity candidate amycretin.

Find latest cybersecurity news from every corner of the globe at Reuters.com, your online source for breaking international news coverage.

The New York Times seeks the truth and helps people understand the world. With 1,700 journalists reporting from more than 150 countries, we provide live updates, investigations, photos and video ...

Artificial intelligence that detects surgical site infections from patient-submitted photos with 73% accuracy could enhance patient care and also reduce clinician burdens following surgeries.

Follow the latest Immigration news stories and headlines. Get breaking news alerts when you download the ABC News App and subscribe to Immigration notifications.